Construction of Recombinant BCGs Overexpressing Antigen 85 Complex and Their Protective Efficacy against Mycobacterium tuberculosis Infection in a Mouse Model.
10.4046/trd.2004.57.2.125
- Author:
Seung Heon LEE
1
;
Bo Young JEON
;
Young Gil PARK
;
Hye Young LEE
;
Sang Nae CHO
;
Hyo Joon KIM
;
Gill Han BAI
Author Information
1. Department of Molecular Biology, Korean Institute of Tuberculosis, Seoul, Korea. gbai@hotmail.com
- Publication Type:Original Article
- Keywords:
Tuberculosis;
Vaccine;
Recombinant BCG
- MeSH:
Animals;
BCG Vaccine;
Electrophoresis, Polyacrylamide Gel;
Humans;
Mice*;
Mycobacterium bovis*;
Mycobacterium tuberculosis*;
Mycobacterium*;
Parents;
Tuberculosis
- From:Tuberculosis and Respiratory Diseases
2004;57(2):125-131
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tuberculosis (TB) remains an enormous global health problem, and a new vaccine against TB more potent than the current inadequate BCG vaccine is urgently needed. We constructed three recombinant Mycobacterium bovis BCG (rBCG) strains over-expressing antigen (Ag) 85A, Ag85B, or both of M. tuberculosis using their own promoter and secretory sequence, or hsp60 promoter. SDS-PAGE analysis of rBCG proteins showed over-expression of Ag85A and Ag85B proteins in higher level than of those in their parental strain of BCG. In addition, rBCG(rBCG/B.FA) over-expressing Ag85A and Ag85B induced strong IFN-gamma production in splenocytes. However, there was no significant difference in protective efficacy between rBCG and their parental BCG strain. In this study, therefore, rBCG over-expressing Ag85A, Ag85B, or both failed to show enhanced protection against M. tuberculosis infection in a mouse model.
